Insulet Corp (PODD)
197.19
+1.03
(+0.53%)
USD |
NASDAQ |
Jul 02, 16:00
197.03
-0.16
(-0.08%)
After-Hours: 20:00
Insulet SG&A Expense (Annual): 734.90M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 734.90M |
December 31, 2022 | 587.80M |
December 31, 2021 | 466.00M |
December 31, 2020 | 384.00M |
December 31, 2019 | 298.00M |
December 31, 2018 | 248.00M |
December 31, 2017 | 208.90M |
December 31, 2016 | 166.08M |
December 31, 2015 | 138.80M |
December 31, 2014 | 108.10M |
December 31, 2013 | 119.77M |
Date | Value |
---|---|
December 31, 2012 | 103.95M |
December 31, 2011 | 87.32M |
December 31, 2010 | 61.36M |
December 31, 2009 | 64.42M |
December 31, 2008 | 63.48M |
December 31, 2007 | 30.06M |
December 31, 2006 | 14.55M |
December 31, 2005 | 9.261M |
December 31, 2004 | 5.127M |
December 31, 2003 | 0.546M |
December 31, 2002 | 3.214M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
298.00M
Minimum
2019
734.90M
Maximum
2023
494.14M
Average
466.00M
Median
2021
SG&A Expense (Annual) Benchmarks
Abbott Laboratories | 10.95B |
ResMed Inc | 874.00M |
Tandem Diabetes Care Inc | 352.50M |
Integra Lifesciences Holdings Corp | 656.64M |
OraSure Technologies Inc | 94.51M |